Search results
Results From The WOW.Com Content Network
Various ototoxic effects are manifested by using antimalarial drugs, with dizziness being one of the most common one. Other effects include vestibular symptoms, hearing loss and tinnitus, which can appear to be both temporary or permanent. [25] Nonetheless, the underlying mechanisms of antimalarial-induced ototoxicity are still poorly understood.
Blurred vision; Dyspnoea (shortness of breath) Tinnitus (ringing in the ears) Migraine; Stevens–Johnson syndrome/toxic epidermal necrolysis (potentially fatal skin reactions) Motorial weakness; Creatinine increase; Elevated liver enzymes; Hepatitis (liver swelling) Stomatitis (mouth swelling) Liver failure; Pulmonary oedema (fluid in the ...
According to EveryDayHealth.com, Tinnitus can be a side effect of certain medications -- including antibiotics, non-steroidal anti-inflammatory drugs, cancer drugs, and even aspirin when taken in ...
More than 260 medications have been reported to cause tinnitus as a side effect. [41] Tinnitus can also occur from the discontinuation of therapeutic doses of benzodiazepines. It can sometimes be a protracted symptom of benzodiazepine withdrawal and may persist for many months. [42] [43] Medications such as bupropion may also cause tinnitus. [44]
Ototoxicity is the property of being toxic to the ear (oto-), specifically the cochlea or auditory nerve and sometimes the vestibular system, for example, as a side effect of a drug. The effects of ototoxicity can be reversible and temporary, or irreversible and permanent. It has been recognized since the 19th century. [1]
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
SARMs are sometimes claimed to be non-virilizing (non-masculinizing). [19] [71] In actuality however, SARMs are largely uncharacterized clinically in terms of potential virilizing effects. [6] In addition, SARMs cannot be aromatized to estrogen, thus causing no estrogenic side effects, for instance gynecomastia. [30] [19] [7]
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...